

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>Bardwell Kathleen</u>			2. Issuer Name and Ticker or Trading Symbol <u>Steris plc [STE]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Sr.V. P. & C.C.O.</u>		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) <u>11/02/2015</u>			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person		
<u>C/O CHANCERY HOUSE, 190 WATERSIDE RD. HAMILTON INDUSTRIAL PARK</u>			4. If Amendment, Date of Original Filed (Month/Day/Year)					
(Street) <u>LEISCESTER X0 LE5 1QZ</u>								
(City) (State) (Zip)								

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Ordinary Shares, ?0.10 Nominal Value	11/02/2015		A		15,731 ⁽¹⁾	A	(2)	15,731	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Amount or Number of Shares
Employee Stock Option (right to buy)	\$22.83	11/02/2015		A		962		(3)	05/21/2019	Ordinary Shares, ? 0.10 Nominal Value	962	(3)	962	D	
Employee Stock Option (right to buy)	\$34.23	11/02/2015		A		1,000		(4)	11/12/2019	Ordinary Shares, ? 0.10 Nominal Value	1,000	(4)	1,000	D	
Employee Stock Option (right to buy)	\$31.87	11/02/2015		A		4,275		(5)	05/20/2020	Ordinary Shares, ? 0.10 Nominal Value	4,275	(5)	4,275	D	
Employee Stock Option (right to buy)	\$36.09	11/02/2015		A		4,000		(6)	05/31/2021	Ordinary Shares, ? 0.10 Nominal Value	4,000	(6)	4,000	D	
Employee Stock Option (right to buy)	\$29.94	11/02/2015		A		3,795		(7)	05/30/2022	Ordinary Shares, ? 0.10 Nominal Value	3,795	(7)	3,795	D	
Employee Stock Option (right to buy)	\$45.34	11/02/2015		A		5,360		(8)	05/31/2023	Ordinary Shares, ? 0.10 Nominal Value	5,360	(8)	5,360	D	
Employee Stock Option (right to buy)	\$53.52	11/02/2015		A		7,000		(9)	05/30/2024	Ordinary Shares, ? 0.10 Nominal Value	7,000	(9)	7,000	D	
Employee Stock Option (right to buy)	\$67.98	11/02/2015		A		10,000		(10)	08/10/2025	Ordinary Shares, ? 0.10 Nominal Value	10,000	(10)	10,000	D	

Explanation of Responses:

1. 6,805 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 450 on May 31, 2016; 1,155 on May 31, 2016; 450 on May 31, 2017; 750 on May 30, 2016; 750 on May 30, 2017; 750 on May 30, 2018; 625 on May 30, 2016; 625 on May 29, 2017; 625 on May 28, 2018 and 625 on May 28, 2019.
2. Represents ordinary shares of STERIS plc ("New STERIS") acquired pursuant to merger of a wholly-owned subsidiary of New STERIS with and into STERIS Corporation ("STERIS"), with STERIS surviving the merger as a wholly-owned subsidiary of New STERIS (the "Merger"), in exchange for common shares of STERIS, which was consummated simultaneous with and conditioned on New STERIS' acquisition of Synergy Health plc by commencing a "recommended offer" under English law. At the effective time of the Merger, each STERIS common share was cancelled and converted into the right to receive one New STERIS ordinary share.
3. This option to purchase 962 New STERIS ordinary shares, which is fully vested, was received in the Merger in exchange for an option to purchase 962 STERIS common shares for \$22.83 per share, subject to the same terms and conditions as the original STERIS stock option.
4. This option to purchase 1,000 New STERIS ordinary shares, which is fully vested, was received in the Merger in exchange for an option to purchase 1,000 STERIS common shares for \$34.23 per share, subject to the same terms and conditions as the original STERIS stock option.
5. This option to purchase 4,275 New STERIS ordinary shares, which is fully vested, was received in the Merger in exchange for an option to purchase 4,275 STERIS common shares for \$31.87 per share, subject to the same terms and conditions as the original STERIS stock option.
6. This option to purchase 4,000 New STERIS ordinary shares, which is fully vested, was received in the Merger in exchange for an option to purchase 4,000 STERIS common shares for \$36.09 per share, subject to the same terms and conditions as the original STERIS stock option.
7. This option became or will become exercisable as follows: 948 on May 30, 2013; 949 on May 30, 2014; 949 on May 30, 2015 and 949 on May 30, 2016. This option was received in the Merger in exchange for an option to purchase 3,795 STERIS common shares for \$29.94 per share, subject to the same terms and conditions as the original STERIS stock option.
8. This option became or will become exercisable as follows: 1,340 on May 31, 2014; 1,340 on May 31, 2015; 1,340 on May 31, 2016 and 1,340 on May 31, 2017. This option was received in the Merger in exchange for an option to purchase 5,360 STERIS common shares for \$45.34 per share, subject to the same terms and conditions as the original STERIS stock option.
9. This option became or will become exercisable as follows: 1,750 on May 30, 2015; 1,750 on May 30, 2016; 1,750 on May 30, 2017 and 1,750 on May 30, 2018. This option was received in the Merger in exchange for an option to purchase 7,000 STERIS common shares for \$53.52 per share, subject to the same terms and conditions as the original STERIS stock option.
10. This option will become exercisable as follows: 2,500 on May 28, 2016; 2,500 on May 28, 2017; 2,500 on May 28, 2018 and 2,500 on May 28, 2019. This option was received in the Merger in exchange for an option to purchase 10,000 STERIS common shares for \$67.98 per share, subject to the same terms and conditions as the original STERIS stock option.

Remarks:

/s/ Dennis P. Patton,
Authorized Representative 11/02/2015
under Power of Attorney

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.